The KU Leuven-led RABYD-VAX consortium is all set to develop a new vaccine against rabies and yellow fever.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vaccines for these two diseases already exist but there are several drawbacks that hinder their efficient distribution.

Rabies is usually transmitted through dog bites, reported a near 100% fatality rate, and claims an estimated 59,000 lives every year.

KU Leuven Laboratory of Virology RABYD-VAX coordinator Johan Neyts said: “Most of these patients live in rural areas in Africa and Asia.

“More than half of the victims are children. Many people are still not vaccinated because the vaccines are very expensive and they need to be transported and stored at cool temperatures.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Many people are still not vaccinated because the vaccines are very expensive and they need to be transported and stored at cool temperatures."

Every year, about 30,000 people are dying because of the mosquito-borne virus yellow fever that can cause a life-threatening infection with jaundice, systemic bleeding, shock, and organ failure.

Set to be included in routine childhood vaccinations, the new vaccine is expected to be safe, temperature-stable and easy to produce.

RABYD-VAX received a grant of €4.1m from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement no. 733176.

The consortium includes researchers from KU Leuven, the Belgian Scientific Institute of Public Health, the Biomedical Primate Research Center in Netherlands and the Animal and Plant Health Agency in the UK.

Image: The new vaccine would be safe, temperature-stable and easy to produce. Photo: © KU Leuven.